PROCEPT BioRobotics Quarterly Cash Flow Statement
NASDAQ: PRCTHealth CareMedical/Dental InstrumentsUSD
18.40+0.50 (+2.79%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
PROCEPT BioRobotics free cash flow
In the quarter ended Jun 30, 2026, PROCEPT BioRobotics generated -$19.3 million of operating cash flow and spent $3.0 million on capital expenditures. That left free cash flow of -$22.2 million, a free-cash-flow margin of -23.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
PROCEPT BioRobotics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -26.86M | -31.64M | -29.84M | -21.41M | -19.58M | -24.74M | -18.86M | -20.97M | -25.63M | -25.96M | -27.50M | -24.62M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 1.99M | 1.74M | 1.71M | 1.62M | 1.59M | 1.48M | 1.45M | 1.33M | 1.27M | 1.18M | 1.32M | 1.05M |
| Stock-Based Compensation | 14.53M | 13.07M | 10.84M | 14.49M | 12.16M | 10.11M | 9.09M | 8.51M | 7.99M | 6.26M | 4.98M | 5.33M |
| Change in Working Capital | -12.54M | -18.43M | 7.02M | -5.77M | -9.35M | 1.63M | -25.70M | -11.13M | -4.44M | -10.23M | -6.01M | -4.22M |
| Operating Cash Flow | -19.25M | -38.13M | -10.33M | -6.63M | -15.04M | -16.98M | -32.39M | -18.80M | -15.74M | -32.29M | -24.79M | -18.94M |
| Capital Expenditures | -2.95M | -2.91M | -1.85M | -2.87M | -2.80M | -1.84M | -1.17M | -246.00K | -1.04M | -1.95M | -8.71M | -5.78M |
| Investing Cash Flow | -2.95M | -2.91M | -1.85M | -2.87M | -2.80M | -1.84M | -1.17M | -246.00K | -1.04M | -1.95M | -8.71M | -5.78M |
| Debt Issued | — | — | — | -1.00K | — | — | -2.12M | 0 | — | — | — | — |
| Financing Cash Flow | 4.50M | 222.00K | 4.44M | 1.08M | 4.38M | 1.30M | 170.53M | 1.72M | 5.30M | 2.59M | 2.87M | 162.12M |
| Net Change in Cash | -17.73M | -40.86M | -7.78M | -8.44M | -13.49M | -17.52M | 136.96M | -17.33M | -11.48M | -31.65M | -30.64M | 137.40M |
| Free Cash Flow | -22.20M | -41.04M | -12.18M | -9.50M | -17.84M | -18.82M | -33.56M | -19.05M | -16.78M | -34.23M | -33.51M | -24.72M |
This table shows 12 quarterly periods of PROCEPT BioRobotics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PRCT's reporting calendar. What is a cash flow statement?